The osteo-metabolic phenotype of COVID-19: an update

Luigi di Filippo1 · Stefano Frara1 · Mauro Doga1 · Andrea Giustina

Received: 30 May 2022 / Accepted: 3 July 2022 / Published online: 20 July 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
Context In the multifaceted COVID-19 clinical scenario characterized by a multi-system disorder with negative implications not only on respiratory function but also on cardiac, hematological, neurological, and endocrine-metabolic systems, a distinctive osteo-metabolic phenotype with an independent influence on disease severity and recovery of patients affected was early reported.
Aim To summarize and update the main evidences regarding the distinct components of this phenotype in acute and Long COVID-19, reinforcing its clinical relevance and discussing the main pathophysiological and clinical-therapeutic implications of the most recent reported findings.
Results This emerging phenotype is characterized by a widespread acute hypocalcemia and hypovitaminosis D with an impaired compensatory parathyroid hormone response, and a high prevalence of skeletal complications such as vertebral fractures. The clinical relevance of this osteo-metabolic phenotype on acute COVID-19 is well characterized, and novel seminal evidences are progressively highlighting its importance also in predicting patient’s long-term outcomes and Long COVID-19 occurrence.
Conclusions These findings reinforced the central role of a multidisciplinary team, including endocrinologists, in evaluating these patients for a proactive search of each aspect of the osteo-metabolic phenotype components since they may represent suitable therapeutic targets to prevent SARS-CoV-2 infection, poor COVID-19 outcomes, Long COVID-19 occurrence and even possibly better responses to COVID-19 vaccination.

Keywords Osteo-metabolic phenotype · Vertebral fractures · COVID-19 · Hypocalcemia · Long-COVID · Vitamin D

Introduction
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a long-lasting pandemic with a dramatic impact worldwide. During the early pandemic spread, several emerging findings have progressively defined COVID-19 as a multi-system disorder and not only as a respiratory disease, with negative implications on cardiac, hematological, neurological, gastrointestinal and, not surprisingly, also on endocrine and metabolic system [1–5]. Diabetes mellitus and obesity were early identified as frequent comorbidities and independent risk factors for severe COVID-19 [6]. Thyroid and pituitary disorders were reported as disease complications possibly due to the inflammatory-(auto)immune dysfunctions and/or direct viral damage since the ubiquitous tissue presence of the angiotensin-converting enzyme 2 (ACE2), the main recognized receptor for SARS-CoV-2 entry [7–9]. In this multifaceted COVID-19 endocrine scenario, a distinctive osteo-metabolic phenotype with an independent influence on disease severity and recovery of patients affected, was early reported [10]. This phenotype is characterized by a widespread acute hypocalcemia, hypovitaminosis D with an impaired compensatory parathyroid hormone (PTH) response, and high prevalence of skeletal complications such as vertebral fractures (VFs).

Aim of this review is to summarize and update the main evidences regarding the distinct components of the osteo-metabolic phenotype in COVID-19, discussing main pathophysiological and clinical-therapeutic implications of the most recent reported findings and understanding if this

Andrea Giustina
giustina.andrea@hsr.it

1 Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

* Andrea Giustina
Andrea.Giustina@hsr.it
phenotype is somewhat strengthened and reinforced in its clinical relevance by recent literature.

**Hypocalcemia**

During the first pandemic spread in Europe, low calcium levels early appeared as a very common biochemical finding. Starting from the first seminal observation showing a case of severe acute hypocalcemia in an Italian patient previously thyroidectomized with SARS-CoV-2 infection [11], several studies conducted worldwide, in order to evaluate the possible causal or casual relationship between COVID-19 and hypocalcemia, reported an unexpected high prevalence of low calcium levels, ranging from 62.6 to 87.2% of patients, depending on the hypocalcemia definition used [12–15].

Hypocalcemia was identified as a distinctive specific feature of COVID-19 reported more frequently in patients affected by SARS-CoV-2 infection than in those with other viral or bacterial pneumonia presenting with the same baseline clinical parameters [16, 17]. Moreover, hypocalcemia was highly prevalent even in non-severe COVID-19 patients, possibly implying that it was intrinsic to the disease and not-only influenced by acute illness [18].

Calculated levels were negatively associated with inflammatory, coagulopathy and organ-injury parameters, and hypocalcemia was recognized as an independent risk factor for COVID-19 worse outcomes [13–15], representing a strongly reliable and easy-to-measure biomarker of disease severity. These findings were confirmed by following systematic reviews and meta-analyses reporting that hypocalcemia was significantly associated with disease severity, hospitalization, length of hospitalization, admission to the intensive care unit and mortality risk [19, 20].

Several pathophysiological factors have been hypothesized to potentially play a role in determining hypocalcemia in COVID-19 [12, 21] (Fig. 1). These mechanisms include calcium-dependent viral mechanisms of action determining intra and extra-cellular cation dysmetabolism [22–24], tissues calcium deposits detected at autopic evaluation [25], acute muscle calcium precipitation [26], calcium role in coagulation and prothrombotic status [27, 28], acute malnutrition during critical illness [29], high levels of unbound and unsaturated fatty acids in inflammatory responses [30] and high prevalence of hypovitaminosis D with an impaired compensatory PTH response [31]. Furthermore, severe hypocalcemia, although not frequently found in COVID-19 [3, 13], may compromise outcome per se due to its additional negative cardiovascular and neurological impact [3, 13]. Thus, since hypocalcemia is a frequent biochemical

---

**Fig. 1** The proposed pathophysiological mechanisms underlying hypocalcemia in COVID-19. Red solid arrow lines indicate the negative influence of the main pathophysiological mechanisms (Vitamin D deficiency; Impaired compensatory PTH response; viral calcium-dependent mechanisms of actions; cytokines and UFAs hypersecretion; acute malnutrition; coagulopathy; tissue calcium deposit) on hypocalcemia occurrence; red dashed arrow lines indicate the negative influence between each of these mechanisms.
finding in patients with acute COVID-19 predicting poor clinical outcomes, we find reasonable to measure in these patients calcium levels at hospital admission, and to monitor them during hospitalization. In particular, severe and acute hypocalcemia can represent a life-threatening emergency with possible negative cardiovascular and neurological complications potentially fatal in hospitalized patients with severe COVID-19 who are per se at risk of developing such complications [32]. Therefore, despite the absence of specific guidelines [33], it can be considered to provide an adequate replacement treatment in those with moderate to severe or symptomatic hypocalcemia according to published recommendations for treatment of hypoparathyroidism [34] which based on the severity of hypocalcemia range from oral calcium and Vitamin D3 or active Vitamin D (VD) supplements to intravenous calcium gluconate. Finally, in COVID-19 survivors, more than 3 months after negative test for SARS-CoV-2, a non-significant difference in calcium levels was observed compared to healthy matched for age and sex subjects, possibly confirming the casual relationship between COVID-19 and hypocalcemia, and its transient nature once the patient recovered from the acute viral syndrome [35]. These data does not entirely support a routine estimation of serum calcium in all post-COVID-19 patients [36]. However, it appears reasonable to assess calcium and VD levels in the follow-up of patients with symptomatic hypocalcemia during the acute disease and eventually consider to supplement VD in those with persistently altered biochemical results.

Hypovitaminosis D

A tight link between VD and COVID-19 was hypothesized from the early pandemic spreading due to the VD well known involvement in immune response and immunocompetence both regarding innate and adaptive immunity [37, 38]. VD is known to have antimicrobial roles and antiviral mechanisms of actions, and to regulate the adaptive immune response promoting a shift from proinflammatory to tolerogenic state downregulating the immune responses mediated by T-helper-1 lymphocytes cells, inhibiting the production of pro-inflammatory cytokines and promoting regulatory T cells maturation [39, 40].

Due to its important immune-modulating role and its widespread deficiency particularly in European Mediterranean Countries (which were heavily impacted by the pandemic), hypovitaminosis D was early reported as a possible risk factor for SARS-CoV-2 infection, severe COVID-19 and worse clinical outcomes. These only-observational findings were confirmed by several large systematic reviews and meta-analyses involving nearly 2 million adults, strongly suggesting the negative impact of hypovitaminosis D in COVID-19 patients [41–44].

In the light of the known pathophysiological role of VD and hypovitaminosis D underlying the main conditions and comorbidities related to severe COVID-19, such as older age [45], male sex [46, 47], diabetes mellitus [6, 48, 49], visceral adiposity/overweight/obesity [50, 51], and hypocalcemia, VD deficiency was suggested to represent the possible common denominator of the endocrine phenotype of COVID-19 [52], as confirmed also by the observational data reporting high prevalence of low VD levels particularly in older, male, diabetic and overweight patients [53, 54]. Given these data, VD was suggested to have a primary role in the prevention of infection and severe disease and reaching an adequate VD level especially in the population at high risk of both hypovitaminosis D and COVID-19 was recommended as a preventive measure [55, 56]. The effect of VD supplementation in general population and in COVID-19 patients was evaluated by several observational studies and randomized controlled trials, with different treatment strategies, reporting initially contrasting results. However, recent systematic reviews and meta-analyses concluded that VD supplementation was strongly effective in reducing rates of viral test positivity and COVID-19 severity [57–60].

Besides the above reported role of hypovitaminosis D in acute COVID-19, its function in patients’ recovery after acute infection and in the pathophysiology of the Long-COVID or Post-acute COVID-19 syndrome characterized especially by neuromuscular, respiratory, and nutritional disorders [61, 62] is still poorly evaluated. VD is known to play key-roles in several metabolic pathways involved in musculoskeletal health [51], and, in previous studies, VD supplementation was proven to provide a muscle recovery benefit after intense physical and damaging stress [63–65]. VD levels were also reported to predict and influence illness duration and time until recovery after acute severe pneumonia [66]. To date, the VD role in Long-COVID occurrence was investigated by only few small studies. A recent pilot-study that included elderly patients after acute COVID-19 reported the efficacy of a six-weeks 2.000 IU/day cholecalciferol therapy vs placebo in reducing creatinine kinase values and in showing a positive improvement trend in the general and physical health status [67]. In two other recent studies, no associations between VD levels and the post-COVID symptoms were observed [68, 69].

Nevertheless, it is widely recommended that an appropriate nutritional status evaluation and a personalized dietary management, including VD supplementation, may represent one the best strategy to facilitate COVID-19 survivors’ recovery [70].

Finally, based on the VD immunomodulatory effects, a possible role of hypovitaminosis D in regulating the anti-SARS-CoV-2 vaccination response and the possible VD deficiency-related vaccine side effects [71], should be
investigated, although recent findings on anti-COVID vaccination and previous studies on other vaccinations reported contrasting results [72–76].

**Impaired compensatory PTH response and hypoparathyroidism**

Among the pathophysiological mechanisms underlying hypocalcemia occurrence in COVID-19, in addition to the high prevalence of VD deficiency, a not-adequate compensatory PTH response was recently proposed. VD is a crucial hormone for calcium homeostasis increasing its intestinal absorption and, in subjects with hypovitaminosis D, the increase in PTH (secondary hyperparathyroidism) generally maintains eucalcemia [77].

Severe acute hypocalcemia cases in COVID-19 patients due to the worsening of previous controlled postsurgical and/or primary hypoparathyroidism have been reported [11, 78], suggesting that hypocalcemia in COVID-19 could occur due the acute combination of low VD levels not adequately compensated by PTH response.

Interestingly, a recent study reported that hypocalcemia occurred prevalently in a context of a marked hypovitaminosis D not adequately compensated by secondary hyperparathyroidism, since, despite most of patients presented with quite severe VD deficiency and hypocalcemia, only one-fifth of them had secondary hyperparathyroidism [31]. Other observational studies seem to confirm this evidence: in fact, PTH median levels of 44.2 pg/mL were reported in 162 COVID-19 patients with VD levels below 20 ng/mL [79] and secondary hyperparathyroidism occurred in only 43.3% of 97 COVID-19 patients characterized by a median VD level of 21 ng/mL [80].

The mechanism underlying this impaired PTH response to hypovitaminosis D and hypocalcemia in COVID-19 is yet to be understood. Parathyroid gland function may be impaired during systemic inflammatory response with increased circulating cytokines [81]. In addition, respiratory alkalosis, typically observed in COVID-19, was reported to increase the PTH resistance at renal receptor level, resulting in hypocalcemia without increase in PTH levels [82]. Moreover, previous autopic studies conducted during SARS epidemic identified viral RNA and antigenic materials in parathyroid gland cells, and expression of ACE2 receptors in parathyroid glands cells has been, although not consistently, reported [83, 84]. Therefore, SARS-CoV-2 may potentially directly affect the parathyroid glands by binding the ACE2 receptors. Supporting this hypothesis, in the literature also three case reports of new-onset primary hypoparathyroidism due to SARS-CoV-2 infection have been reported [85–87]. Finally, both hypermagnesemia and severe hypomagnesemia were reported in COVID-19 patients [88, 89]. Since altered magnesium levels may suppress PTH secretion it can be hypothesized that they may play a role in the determinism of functional hypoparathyroidism [90].

**Skeletal complications and vertebral fractures**

Morphometric VFs are one of the most relevant clinical manifestations of osteoporosis and skeletal fragility and have been recently reported to be highly prevalent in COVID-19 patients [91]. In the literature, VFs are associated with decreased survival, reduction of respiratory function and impaired quality of life in the general population [91, 92].

In a previous study, COVID-19 patients presenting with VFs required noninvasive mechanical ventilation more frequently and their mortality rate was almost doubled compared to non-fractured patients [84]. Following studies conducted on different patient cohorts partly confirmed these data showing a high prevalence of VFs in COVID-19 patients and a negative influence of lower bone mineral density (BMD) on patient outcomes [93–95].

In fact, in hospitalized COVID-19 patients, several concomitant factors may lead to an increased fracture risk [96–99], such as advanced age and comorbidities including diabetes, cardiovascular diseases and hypertension [100].

Moreover, as reported above, hospitalized COVID-19 patients frequently show hypovitaminosis D, which is known to be associated with lower BMD and increased fractures risk [77]. However, in the available studies on VFs in COVID-19, VD levels were not so far reported.

VF and decreased BMD are known to increase risk of pneumonia and to impair respiratory function leading to a restrictive pulmonary dysfunction in general population [101–103]. A very recent study, assessing the clinical impact of VFs in COVID-19 survivors on their medium term follow-up respiratory recovery, reported that patients with VFs, detected at hospital admission, had impaired respiratory function compared to those without VFs showing worse spirometric parameters and higher rate of pulmonary function tests abnormalities at six-month follow-up, despite patients in both groups presenting similar acute infectious lung involvement at hospital admission [104]. Therefore, VFs appear to also influence the medium-term impaired respiratory function of COVID-19 survivors which, in turn, may significantly influence their recovery and contribute to Long-COVID occurrence.

These findings suggest that VFs assessment at baseline may help in identifying patients at higher risk of worse clinical outcomes and those needing a more intensive respiratory follow-up. Moreover, patients showing persistent respiratory impairment without evidence of pulmonary
disease may benefit from a VF's assessment to prevent the vicious circle of further fractures and respiratory deterioration. Therefore, as anti-osteoporotic treatments, including denosumab, do not only appear to cause an increased predisposition to COVID-19 [105] but even seem to reduce disease risk [106, 107], they should be continued during the pandemic and vaccination campaigns to avoid an increased fracture risk, detrimental in the context of COVID-19 [108].

Conclusions

In conclusion, in the context of the endocrine and metabolic complications of COVID-19, recent literature confirmed the existence, strengthening its clinical relevance, of a distinct osteo-metabolic phenotype which we originally and seminally reported. Specifically, it has recently emerged that high rate of acute hypocalcemia likely occurs in the context of a widespread hypovitaminosis D and of a not adequate compensatory PTH response possibly due also to a direct involvement of the parathyroids in SARS-CoV-2 infection. Moreover, high prevalence of VFs was recently highlighted not only as predictor of poor outcome in acute COVID-19 but also of inadequate respiratory recovery in COVID-19 survivors. The clinical relevance of the osteo-metabolic phenotype on short-and long-term outcomes of the disease confirms the important role of the endocrinologist in the COVID-19 multidisciplinary team [109] for proactive search of the different contributing components since they may all represent suitable therapeutic targets to prevent SARS-CoV-2 infection, poor COVID-19 outcomes, Long-COVID occurrence and even possibly better responses to COVID-19 vaccination.

Author contributions All authors contributed equally.

Compliance with ethical standards

Conflict of interest The authors declare no competing interests.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. A. Gupta, M.V. Madhavan, K. Sehgal et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 26(7), 1017–1032 (2020). https://doi.org/10.1038/s41591-020-0966-3
2. M. Puig-Domingo, M. Marazuela, A. Giustina. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine 68(1), 2–5 (2020). https://doi.org/10.1007/s12020-020-02294-5
3. M. Puig-Domingo, M. Marazuela, B.O. Yildiz, A. Giustina. COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. Endocrine 72(2), 301–316 (2021). https://doi.org/10.1007/s12020-021-02734-w
4. M. Marazuela, A. Giustina, M. Puig-Domingo. Endocrine and metabolic aspects of the COVID-19 pandemic [published correction appears in Rev Endocr Metab Disord. 2021 Mar;22(1):145]. Rev. Endocr. Metab. Disord. 21(4), 495–507 (2020). https://doi.org/10.1007/s11154-020-09569-2
5. A. Giustina, J.P. Bilezikian. Revisiting the endocrine and metabolic manifestations of COVID-19 two years into the pandemic. Rev. Endocr. Metab. Disord. 23(2), 133–136 (2022). https://doi.org/10.1007/s11154-022-09716-x
6. Y. Zhou, J. Chi, W. Lv, Y. Wang. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab. Res. Rev. 37(2), e3377 (2021). https://doi.org/10.1002/dmrr.3377
7. L. Scappaticcio, F. Ptitio, K. Esposito, A. Piccardo, P. Trimboli. Impact of COVID-19 on the thyroid gland: an update. Rev. Endocr. Metab. Disord. 22(4), 803–815 (2021). https://doi.org/10.1007/s11154-020-09615-z
8. S. Frara, A. Allora, L. Castellino, L. di Filippo, P. Loli, A. Giustina, COVID-19 and the pituitary. Pituitary 24(3), 465–481 (2021). https://doi.org/10.1007/s11120-021-01148-1
9. S. Frara, P. Loli, A. Allora et al. COVID-19 and hypopituitarism. Rev. Endocr. Metab. Disord. 23(2), 215–231 (2022). https://doi.org/10.1007/s11154-021-09672-y
10. L. di Filippo, S. Frara, A. Giustina. The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects. Rev. Endocr. Metab. Disord. 17(5), 445–446 (2021). https://doi.org/10.10038/s11574-021-00516-y
11. S. Bossoni, L. Chiesa, A. Giustina, Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection. Endocrine 68(2), 253–254 (2020). https://doi.org/10.1007/s12020-020-03226-0
12. L. di Filippo, M. Doga, S. Frara, A. Giustina. Hypocalcemia in COVID-19: Prevalence, clinical significance and therapeutic implications. Rev. Endocr. Metab. Disord. 23(2), 299–308 (2022). https://doi.org/10.1007/s11154-021-09655-z
13. L. Di Filippo, A.M. Formenti, P. Rovere-Querini et al. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. Endocrine 68(3), 475–478 (2020). https://doi.org/10.1007/s12020-020-0383-5
14. J. Liu, P. Han, J. Wu, J. Gong, D. Tian. Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J. Infect. Public Health 13(9), 1224–1228 (2020). https://doi.org/10.1016/j.jiph.2020.05.029
15. J.K. Sun, W.H. Zhang, L. Zou et al. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging (Albany NY) 12(12), 11287–11295 (2020). https://doi.org/10.18632/aging.103526
16. L. di Filippo, A.M. Formenti, M. Doga et al. Hypocalcemia is a distinctive biochemical feature of hospitalized COVID-19 patients. Endocrine 71(1), 9–13 (2021). https://doi.org/10.1007/s12020-020-02541-9
17. M. Mehta, H. Ghanii, F. Chua et al. Retrospective case-control study to evaluate hypocalcaemia as a distinguishing feature of COVID-19 compared with other infective pneumonias and its association with disease severity. BMJ Open. 11(12), e053810 (2021). https://doi.org/10.1136/bmjopen-2021-053810
18. R. Pal, S. Ram, D. Zohmannai et al. High prevalence of hypocalcaemia in non-severe COVID-19 patients: a retrospective case-control study. Front. Med. (Lausanne) 7, 590805 (2021). https://doi.org/10.3389/fmed.2020.590805
19. E. Alemzadeh, E. Alemzadeh, M. Ziaee, A. Abedi, H. Salehniya, The effect of low serum calcium level on the severity and mortality of Covid patients: a systematic review and meta-
29. L. Di Filippo, A.M. Formenti, A. Giustina, Hypocalcemia: the quest for the cause of a major biochemical feature of COVID-19. Endocrine 70(3), 463–464 (2020). https://doi.org/10.1007/s12020-020-02525-9

30. J.P. Bilezkiyan, D. Bickle, M. Hewison et al. Mechanisms in endocrinology: vitamin D and COVID-19. Eur. J. Endocrinol. 183(5), R133–R147 (2020). https://doi.org/10.1530/EJE-20-0665

31. N. Charoenngam, M.F. Holick, Immunologic effects of vitamin D on human health and disease. Nutrients 12(7), 2097 (2020). https://doi.org/10.3390/nu12072097

32. H.A. Dissanayake, N.L. de Silva, M. Sumanatilleke et al. Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 107(5), 1484–1502 (2022). https://doi.org/10.1210/clinem/dgab892

33. R. Hopefl, M. Ben-Efrïki, S. Deb, Association between vitamin D levels and inflammatory markers in COVID-19 patients: a meta-analysis of observational studies. J. Pharm. Pharm. Sci. 25, 124–136 (2022). https://doi.org/10.18433/jpps32518

34. M.R. Akbar, A. Wibowo, R. Pranata, B. Setiabudiawan, Low Vitamin D on Human health and disease. Nutrients 12(7), 2097 (2020). https://doi.org/10.3390/nu12072097

35. A. Giustina, R.A. Adler, N. Binkley et al. Controversies in vitamin D on human health and disease. Nutrients 12(7), 2097 (2020). https://doi.org/10.3390/nu12072097

36. A. Giustina, R.A. Adler, N. Binkley et al. Controversies in vitamin D: summary statement from an international conference. J. Clin. Endocrinol. Metab. 104(2), 234–240 (2019). https://doi.org/10.1210/jc.2018-01414

37. A. Giustina, R.A. Adler, N. Binkley et al. Consensus statement from 2nd International Conference on Controversies in Vitamin D. Rev. Endocrin. Metab. Disord. 21(1), 89–116 (2020). https://doi.org/10.1007/s11154-019-09532-w

38. M.L. Brandi, A. Giustina, Sexual dimorphism of coronavirus 19 morbidity and lethality. Trends Endocrinol. Metab. 31(12), 918–927 (2020). https://doi.org/10.1615/s01678581.202009.003

39. E. Maddaloni, I. Cavallari, N. Napoli, C. Conte, Vitamin D and diabetes mellitus. Front Horm. Res. 50, 161–176 (2018). https://doi.org/10.1159/000486083

40. F. Tecilazich, A.M. Formenti, A. Giustina, Role of vitamin D in diabetic retinopathy: pathophysiological and clinical aspects. Rev. Endocr. Metab. Disord. 22(4), 715–727 (2021). https://doi.org/10.1007/s11154-020-09575-4

41. C. Conte, A. Esposito, R. De Lorenzo et al. Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: a post-hoc analysis of a prospective cohort study. Nutr. Metab. Cardiovasc. Dis. 31(7), 2156–2164 (2021). https://doi.org/10.1016/j.numecd.2021.04.020

42. L. Di Filippo, R. De Lorenzo, A. Giustina, P. Rovere-Querini, C. Conte, Vitamin D in osteosarcomatous obesity. Nutrients 14(9), 1816 (2022). https://doi.org/10.3390/nu14091816

43. A. Giustina, Hypovitaminosis D and the endocrine phenotype of COVID-19. Endocrine 72(1), 1–11 (2021). https://doi.org/10.1007/s12020-021-02671-8
84. L. He, Y. Ding, Q. Zhang et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2 cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J. Pathol. 210(3), 288–297 (2006). https://doi.org/10.1002/path.2067
85. S. Elkattawy, R. Alyacoub, S. Ayad, M. Pandya, A. Eckman, A novel case of hypoparathyroidism secondary to SARS-CoV-2 infection. Cureus 12(8), e10097 (2020). https://doi.org/10.7759/cureus.10097
86. M. Dianatfar, M. Sanjari, B. Dalfardi, Hypoparathyroidism After COVID-19 pneumonia. Magnesium 33(30–100), 7 (2021)
87. V.E. Georgakopoulou, P. Avramopoulos, P. Papalexis et al. COVID-19 induced hypoparathyroidism: a case report. Exp. Ther. Med. 23(5), 346 (2022). https://doi.org/10.3892/etm.2022.11276
88. V. Trapani, A. Rosanoff, S. Baniasadi et al. The relevance of magnesium homeostasis in COVID-19. Eur. J. Nutr. 61(2), 625–636 (2022). https://doi.org/10.1007/s00394-021-02704-y
89. R. Sharma, A. Heidari, R.H. Johnson, S. Advani, G. Petersen, Serum magnesium levels in hospitalized patients with SARS-CoV-2. J. Investig. Med. 70(2), 409–414 (2022). https://doi.org/10.1136/jim-2021-01948
90. T. Vetter, M.J. Lohse, Magnesium and the parathyroid. Curr. Opin. Nephrol. Hypertens. 11(4), 403–410 (2002). https://doi.org/10.1097/00041552-200207000-00006
91. L. di Filippo, A.M. Formenti, M. Doga, E. Pedone, P. Rovere-Querini, A. Giustina, Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict disease outcomes. J. Clin. Endocrinol. Metab. 106(2), e602–e614 (2021). https://doi.org/10.1210/clinem/dgaa738
92. T. Jalava, S. Sarna, L. Pulkkinen et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Min. Res. 18(7), 1254–1260 (2003). https://doi.org/10.1359/jbrm.2003.18.7.1254
93. S. Battisti, N. Napoli, C. Pedone et al. Vertebral fractures and mortality risk in hospitalised patients during the COVID-19 pandemic emergency. Endocrine 74(3), 461–469 (2021). https://doi.org/10.1007/s12020-021-02872-1
94. J. Kottlors, N. Große Hokamp, P. Fervers et al. Early extra-pulmonary prognostic features in chest computed tomography in COVID-19 pneumonia: Bone mineral density is a relevant predictor for the clinical outcome - a multicenter feasibility study. Bone 144, 115790 (2021). https://doi.org/10.1016/j.bone.2020.115790
95. M. Tahtabasi, N. Kilicaslan, Y. Akin et al. The prognostic value of vertebral bone density on chest CT in hospitalized COVID-19 patients. J. Clin. Densitom. 24(4), 506–515 (2021). https://doi.org/10.1016/j.jocd.2021.07.007
96. N. Napoli, A.L. Elderkin, D.P. Kiel, S. Khosla, Managing fragility fractures during the COVID-19 pandemic. Nat. Rev. Endocrinol. 16(9), 467–468 (2020). https://doi.org/10.1038/s41574-020-0379-z
97. G.R. Emkey, S. Epstein, Secondary osteoporosis: pathophysiology & diagnosis. Best. Pr. Res Clin. Endocrinol. Metab. 28(6), 911–935 (2014). https://doi.org/10.1016/j.beem.2014.07.002
98. G. Mazzotti, M. Baracca, M. Doga, T. Porcelli, P.P. Vescovi, A. Giustina, Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. Eur. J. Endocrinol. 167(6), 865–872 (2012). https://doi.org/10.1530/EJE-12-0566
99. S. Boussaid, Y. Makhlouf, S. Jammali, H. Sahli, M. Elleuch, S. Rekik, Association of SARS-COV2 and lumbar spine fractures: causal or coincidental? [published online ahead of print, 2021 Nov 26]. J Clin Densitom. 2021;S1094–6950(21)00095-0. https://doi.org/10.1016/j.jocd.2021.11.006
100. G. Mazzotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2022). https://doi.org/10.1007/s12020-011-9570-2
101. B. Kim, J. Kim, Y.H. Jo et al. Risk of pneumonia after vertebral compression fracture in women with low bone density: a population-based study. Spine (Philos. Pa 1976) 43(14), E830–E835 (2018). https://doi.org/10.1097/BRS.000000000002536
102. R. Watanabe, M. Shiraki, M. Saito, R. Okazaki, D. Inoue, Restrictive pulmonary dysfunction is associated with vertebral fractures and bone loss in elderly postmenopausal women. Osteoporos. Int. 29(3), 625–633 (2018). https://doi.org/10.1007/s10198-017-4337-0
103. J.H. Krege, D. Kendler, K. Krohn et al. Relationship between vertebral fracture burden, height loss, and pulmonary function in postmenopausal women with osteoporosis. J. Clin. Densitom. 18(4), 506–511 (2015). https://doi.org/10.1016/j.jocd.2015.02.004
104. L. di Filippo, N. Compagnone, S. Frara, et al. Vertebral fractures at hospitalization predict impaired respiratory function during follow-up of COVID-19 survivors [published online ahead of print, 2022 Jun 8]. Endocrine. 2022. https://doi.org/10.1007/s12020-022-03096-7
105. A.M. Formenti, E. Pedone, L. di Filippo, F.M. Ullivieri, A. Giustina, Are women with osteoporosis treated with denosumab at risk of severe COVID-19. Endocrine 70(2), 203–205 (2020). https://doi.org/10.1007/s12020-020-02500-4
106. J. Blanch-Rubió, N. Soldevila-Domenech, L. Tío et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging (Albany NY) 12(20), 19923–19937 (2020). https://doi.org/10.18632/aging.104117
107. A. Atmaca, I. Demirci, C. Haymana et al. No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study. Osteoporos. Int. 33(1), 273–282 (2022). https://doi.org/10.1007/s00198-021-06067-2
108. E. Tsourdi, E.W. Yu, S.M. Jan de Beur, M.T. Drake, Vaccination for Coronavirus Disease 2019 (COVID-19) and relationship to osteoporosis care: current evidence and suggested approaches. J. Bone Min. Res. 36(6), 1042–1047 (2021). https://doi.org/10.1002/jbmr.4304
109. A. Giustina, M. Marazuela, M. Reincke, B.O. Yildiz, M. Puig-Domingo, One year of the pandemic - how European endocrinologists responded to the crisis: a statement from the European Society of Endocrinology. Eur. J. Endocrinol. 185(2), C1–C7 (2021). https://doi.org/10.1530/EJE-21-0397